Loading search results…

Scholars @ Weill Cornell Medicine

Help & supportPhase 1 prototype

Browse

Scholars8,803 Publications201,993 Funding7,268 Clinical research1,190

Loading search results…

Browse

Scholars8,803 Publications201,993 Funding7,268 Clinical research1,190

FiltersClear all

Status

Recruiting350
Not yet recruiting11
Enrolling by invitation17
Active, not recruiting322
Completed358
Terminated132

Study type

Interventional1,190
Observational101
Expanded access19
Not on ClinicalTrials.gov1,519

Phase

Phase 3325
Not applicable304
Phase 2286
Phase 1103
Phase 1/277
Phase 454

Investigator

Gail J Roboz41
Manish A Shah27
Parag Goyal23
Sonal Kumar23
Scott T. Tagawa22

Show all 50Show fewer

Department

Medicine750
Pediatrics81
Neurology46
Psychiatry46
Obstetrics and Gynecology41

Show all 22Show fewer

Condition

Leukemia, Myeloid, Acute50
Prostatic Neoplasms49
Breast Neoplasms41
Heart Failure31
Neoplasms31

Show all 50

Intervention type

Drug788
Other176
Device166
Biological150
Procedure119
Behavioral83

Sponsor type

Industry685
WCM (investigator-initiated)230
Other academic173
NIH76
Cooperative group25
Unknown1

Start date

Has results posted342

Interventional×Clear all

Showing 101–120 of 1,190 studiesSort:

Active, not recruitingInterventional · Phase 1NCT04052555 ↗
A Phase 1b Study of Berzosertib in Combination With Radiation Therapy to Overcome Therapeutic Resistance in Chemotherapy Resistant Triple Negative and Estrogen and/or Progesterone Receptor Positive, HER2 Negative Breast Cancer
Eleni AndreopoulouPI
Intervention
Drug: Berzosertib · Procedure: Biospecimen Collection · Other: Quality-of-Life Assessment · Other: Questionnaire Administration · Radiation: Radiation Therapy

FiltersClear all

Status

Recruiting350
Not yet recruiting11
Enrolling by invitation17
Active, not recruiting322
Completed358
Terminated132

Study type

Interventional1,190
Observational101
Expanded access19
Not on ClinicalTrials.gov1,519

Phase

Phase 3325
Not applicable304
Phase 2286
Phase 1103
Phase 1/277
Phase 454

Investigator

Gail J Roboz41
Manish A Shah27
Parag Goyal23
Sonal Kumar23
Scott T. Tagawa22

Show all 50Show fewer

Department

Medicine750
Pediatrics81
Neurology46
Psychiatry46
Obstetrics and Gynecology41

Show all 22Show fewer

Condition

Leukemia, Myeloid, Acute50
Prostatic Neoplasms49
Breast Neoplasms41
Heart Failure31
Neoplasms31

Show all 50

Intervention type

Drug788
Other176
Device166
Biological150
Procedure119
Behavioral83

Sponsor type

Industry685
WCM (investigator-initiated)230
Other academic173
NIH76
Cooperative group25
Unknown1

Start date

Has results posted342

Interventional×Clear all

Showing 101–120 of 1,190 studiesSort:

Active, not recruitingInterventional · Phase 1NCT04052555 ↗
A Phase 1b Study of Berzosertib in Combination With Radiation Therapy to Overcome Therapeutic Resistance in Chemotherapy Resistant Triple Negative and Estrogen and/or Progesterone Receptor Positive, HER2 Negative Breast Cancer
Eleni AndreopoulouPI
Intervention
Drug: Berzosertib · Procedure: Biospecimen Collection · Other: Quality-of-Life Assessment · Other: Questionnaire Administration · Radiation: Radiation Therapy

Phase 2/3

Early phase 13

Harini Sarva21
Ashish Saxena20
Cora Sternberg20
Ellen K. Ritchie18
Ruben Niesvizky16
Dana Jeremy Lukin14
Evelyn M. Horn14
Pinkal Desai14
Ellen J Scherl13
Daniel W Skupski12
Eleni Andreopoulou12
Jim W. Cheung12
Jia Ruan12
Massimo Cristofanilli12
Sujit Sheth12
Catherine Butkus Small11
James E. Ip11
John Allan11
Anna C Pavlick10
Alexander Ja-Ho Chou10
Aliza B Solomon10
Alpana P. Shukla10
Marshall J. Glesby10
Anna Podolanczuk9
Barbara Ma9
Catherine McGuinn9
Silvia Chiara Formenti9
Hani Lamie Ashamalla9
Kristen Marks9
Robert J. Kaner9
Shari Lipner9
Maria Teresa DeSancho8
Samuel Kim8
Andrew F. Alexis7
Erin Mulvey7
Evelyn Cantillo7
Jean W. Pape7
Sebastian A. Mayer7
Brian DeRubertis6
Conor Liston6
Darshana M Dadhania6
David M Nanus6
Joseph M Scandura6
Lok W. Yung6
Mehraneh Dorna Jafari6

Neurological Surgery19

Cardiothoracic Surgery17

Urology15

Rehabilitation Medicine13

Population Health Sciences9

Otolaryngology Head and Neck Surgery7

Pathology and Laboratory Medicine1

Pharmacology1

Show fewer

Carcinoma, Non-Small-Cell Lung27
Multiple Myeloma27
Colitis, Ulcerative26
Crohn Disease26
Myelodysplastic Syndromes26
Recurrence25
Atrial Fibrillation23
Neoplasm Metastasis23
Obesity23
Parkinson Disease21
COVID-1920
Colorectal Neoplasms18
Depression18
Cardiovascular Diseases17
Hematologic Neoplasms17
HIV Infections16
Non-alcoholic Fatty Liver Disease15
Overweight15
Melanoma13
Idiopathic Pulmonary Fibrosis12
Inflammatory Bowel Diseases12
Leukemia, Lymphocytic, Chronic, B-Cell12
Lung Neoplasms12
Lymphoma, Non-Hodgkin12
Primary Myelofibrosis12
Hypertension11
Myeloproliferative Disorders11
Alzheimer Disease10
Coronary Artery Disease10
Hypertension, Pulmonary10
Leukemia, Myelomonocytic, Chronic10
Stroke10
Urinary Bladder Neoplasms10
Cognitive Dysfunction9
Leukemia9
Lung Diseases, Interstitial9
Pulmonary Arterial Hypertension9
Burkitt Lymphoma8
Carcinoma, Renal Cell8
Chronic Pain8
Fibrosis8
Lymphoma, Follicular8
Lymphoma, Large B-Cell, Diffuse8
Adenocarcinoma Of Esophagus7
Anemia7

Radiation

Diagnostic test22

Dietary supplement14

Combination product11

Genetic6

Dates

Sep 2020 – Feb 2027 (est.)

Sponsor

National Cancer Institute

Bilateral Breast CarcinomaHER2-Negative Breast CarcinomaLocalized Breast Carcinoma+2 more

Active, not recruitingInterventional · Not applicableNCT04057352 ↗

The Citadel Embolization Device Study

Jared KnopmanPI

Intervention: Device: Citadel Embolization Device
Dates: Jul 2019 – Nov 2026 (est.)
Sponsor: Stryker Neurovascular

Unruptured Wide-neck Aneurysms

RecruitingInterventional · Phase 3NCT04064060 ↗

A Phase 3b, Open-label, Single-arm, Rollover Study to Evaluate Long-term Safety in Subjects Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials

Sujit ShethPI

Intervention: Drug: Luspatercept
Dates: Aug 2019 – May 2028 (est.)
Sponsor: Celgene Corporation

Myelodysplastic Syndromes (MDS)Beta-thalassemiaMyeloproliferative Neoplasm(MPN)-Associated Myelofibrosis

Active, not recruitingInterventional · Phase 1/2NCT04067336 ↗

A Phase 1/2 First in Human Study of the Menin-MLL(KMT2A) Inhibitor KO-539 in Patients With Relapsed or Refractory Acute Myeloid Leukemia

Gail J RobozPI

Intervention: Drug: Ziftomenib · Drug: Midazolam · Drug: Itraconazole
Dates: Sep 2019 – Oct 2028 (est.)
Sponsor: Kura Oncology

Advanced Malignant NeoplasmAcute Myeloid LeukemiaMixed Lineage Leukemia+4 more

Active, not recruitingInterventional · Phase 1/2NCT04068194 ↗

A Phase I/II Study of M3814 and Avelumab in Combination With Hypofractionated Radiation in Patients With Advanced/Metastatic Solid Tumors and Hepatobiliary Malignancies

Elizabeta Cristina PopaPI

Intervention: Drug: Avelumab · Procedure: Biopsy Procedure · Procedure: Biospecimen Collection · Procedure: Computed Tomography · Radiation: Hypofractionated Radiation Therapy · Drug: Peposertib
Dates: Apr 2020 – Jul 2027 (est.)
Sponsor: National Cancer Institute

Locally Advanced Malignant Solid NeoplasmLocally Advanced Unresectable CholangiocarcinomaLocally Advanced Unresectable Gallbladder Carcinoma+7 more

Active, not recruitingInterventional · Phase 2NCT04071223 ↗

A Phase II Randomized Trial of Radium-223 Dichloride and Cabozantinib in Patients With Advanced Renal Cell Carcinoma With Bone Metastasis (RadiCal)

Ana M. MolinaPI

Intervention: Procedure: Biospecimen Collection · Procedure: Bone Scan · Drug: Cabozantinib S-malate · Procedure: Computed Tomography · Procedure: Magnetic Resonance Imaging · Procedure: Positron Emission Tomography · Other: Questionnaire Administration · Radiation: Radium Ra 223 Dichloride
Dates: Jul 2020 – Jul 2026
Sponsor: Alliance for Clinical Trials in Oncology

Advanced Renal Cell CarcinomaChromophobe Renal Cell CarcinomaClear Cell Renal Cell Carcinoma+6 more

RecruitingInterventional · Not applicableNCT04076735 ↗

DIFFIR: Geriatric Distal Femur Fixation Versus Replacement - A Randomized Controlled Trial of Acute Open Reduction Internal Fixation (ORIF) Versus Distal Femoral Replacement (DFR)

William Michael RicciPI

Intervention: Procedure: Distal femoral replacement · Procedure: Surgical Fixation (ORIF)
Dates: Oct 2021 – Dec 2027 (est.)
Sponsor: Weill Medical College of Cornell University

Distal Femur Fracture

Active, not recruitingInterventional · Phase 1/2NCT04086264 ↗

A Phase 1b/2 Study of IMGN632 as Monotherapy or Combination With Venetoclax and/or Azacitidine for Participants With CD123-Positive Acute Myeloid Leukemia

Gail J RobozPI

Intervention: Drug: Azacitidine · Drug: IMGN632 · Drug: Venetoclax
Dates: Nov 2019 – Feb 2027 (est.)
Sponsor: AbbVie Inc.

Acute Myeloid Leukemia

Active, not recruitingInterventional · Not applicableNCT04089059 ↗

A Prospective, Multi-Center, Open Label, Single Arm Clinical Trial Evaluating the Safety and Efficacy of the Cordella™ Pulmonary Artery Sensor System in NYHA Class III Heart Failure Patients (PROACTIVE- HF Trial)

Reema BhattPI

Intervention: Device: Cordella™ Pulmonary Artery Sensor System
Dates: Jan 2020 – Apr 2028 (est.)· Results posted
Sponsor: Endotronix, Inc.

Heart Failure NYHA Class III

Active, not recruitingInterventional · Not applicableNCT04090424 ↗

A Pivotal Study to Assess the Safety and Effectiveness of NovoSorb® Biodegradable Temporizing Matrix (BTM) in the Treatment of Severe Burn Skin Injuries

Philip Hyungjin ChangPI

Intervention: Device: NovoSorb BTM · Procedure: Standard of Care
Dates: Sep 2021 – May 2026 (est.)
Sponsor: PolyNovo Biomaterials Pty. Ltd

Burns

Active, not recruitingInterventional · Phase 3NCT04094688 ↗

Randomized Double-Blind Phase III Trial of Vitamin D3 Supplementation in Patients With Previously Untreated Metastatic Colorectal Cancer (SOLARIS)

Manish A ShahPI

Intervention: Drug: Bevacizumab · Drug: Oxaliplatin · Drug: Leucovorin Calcium · Drug: Fluorouracil · Drug: Irinotecan Hydrochloride · Drug: Irinotecan · Dietary supplement: Cholecalciferol · Other: Quality-of-Life Assessment · Other: Questionnaire Administration
Dates: Oct 2019 – Jul 2024· Results posted
Sponsor: Alliance for Clinical Trials in Oncology

Colorectal Adenocarcinoma

Active, not recruitingInterventional · Phase 3NCT04095364 ↗

A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients With Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or Peritoneum

Evelyn CantilloPI

Intervention: Procedure: Biopsy Procedure · Procedure: Biospecimen Collection · Drug: Carboplatin · Procedure: Imaging Procedure · Drug: Letrozole · Drug: Paclitaxel
Dates: Sep 2019 – Feb 2027 (est.)
Sponsor: NRG Oncology

Low Grade Fallopian Tube Serous AdenocarcinomaOvarian Low Grade Serous AdenocarcinomaPrimary Peritoneal Low Grade Serous Adenocarcinoma+9 more

Active, not recruitingInterventional · Not applicableNCT04095663 ↗

Comparison of Surgery and Medicine on the Impact of Diverticulitis (COSMID) Trial

Steven ChaoPIMehraneh Dorna JafariPI

Intervention: Procedure: Partial Colectomy · Other: Medical Management
Dates: Oct 2019 – Feb 2027 (est.)
Sponsor: University of Washington, The

Diverticulitis

RecruitingInterventional · Not applicableNCT04097145 ↗

A Prospective, Multicenter, Randomized, Controlled Pivotal Trial to Evaluate the Safety and Effectiveness of Transcatheter Tricuspid Valve Repair With the Edwards PASCAL Transcatheter Valve Repair System and Optimal Medical Therapy (OMT) Compared to OMT Alone in Patients With Tricuspid Regurgitation

Shmuel ChenPI

Intervention: Device: Edwards PASCAL System · Drug: Optimal Medical Therapy
Dates: Dec 2019 – Dec 2027 (est.)
Sponsor: Edwards Lifesciences Corp.

Tricuspid RegurgitationTricuspid Valve InsufficiencyTricuspid Valve Disease

RecruitingInterventional · Not applicableNCT04101669 ↗

A Randomized, Multi-Center, Pivotal Efficacy and Safety Study Evaluating the RESET® System for Glycemic Improvement in Patients With Inadequately Controlled Type 2 Diabetes and Obesity

Reem Z. SharaihaPI

Intervention: Device: RESET Liner · Other: Sham
Dates: Sep 2019 – Dec 2027 (est.)
Sponsor: GI Dynamics, Inc.

Diabetes type2Obesity

Active, not recruitingInterventional · Not applicableNCT04112381 ↗

A Pivotal Clinical Trial to Evaluate the Safety and Efficacy of Staged Bilateral Exablate Treatment of Medication Refractory Essential Tremor

Michael G KaplittPI

Intervention: Device: Exablate Model 4000 Type 1.0/1.1
Dates: Jun 2020 – Mar 2026 (est.)
Sponsor: InSightec

Essential Tremor

Active, not recruitingInterventional · Phase 2NCT04115631 ↗

A Randomized 3-Arm Phase II Study Comparing 1.) Bendamustine, Rituximab and High Dose Cytarabine (BR/CR) 2.) Bendamustine, Rituximab, High Dose Cytarabine and Acalabrutinib (BR/CR-A), and 3.) Bendamustine, Rituximab and Acalabrutinib (BR-A) in Patients </= 70 Years Old With Untreated Mantle Cell Lymphoma

John AllanPI

Intervention: Drug: Acalabrutinib · Drug: Bendamustine · Drug: Bendamustine Hydrochloride · Drug: Cytarabine · Biological: Rituximab
Dates: Dec 2019 – Dec 2026 (est.)
Sponsor: ECOG-ACRIN Cancer Research Group

Liver LymphomaMantle Cell Lymphoma

Active, not recruitingInterventional · Phase 1/2NCT04127578 ↗

A Phase 1/2a Open-Label Ascending Dose Study to Evaluate the Safety and Effects of LY3884961 in Patients With Parkinson's Disease With at Least One GBA1 Mutation (PROPEL)

Harini SarvaPI

Intervention: Biological: LY3884961 · Drug: Methylprednisolone · Drug: Sirolimus
Dates: Jan 2020 – Aug 2031 (est.)
Sponsor: Prevail Therapeutics, Inc.

Parkinson Disease

Active, not recruitingInterventional · Not applicableNCT04131907 ↗

A Prospective, Multicenter, Double Blind, Randomized, Clinical Study to Evaluate the Safety and Efficacy of the Optilume™ BPH Catheter System in Men With Symptomatic BPH

Richard LeePI

Intervention: Device: Optilume BPH Catheter System · Device: Optilume Sham Device
Dates: Feb 2020 – Aug 2022· Results posted
Sponsor: Urotronic, Inc.

Benign Prostatic Hyperplasia

RecruitingInterventional · Not applicableNCT04137692 ↗

Red Blood Cell Exchange Transfusion as a Novel Treatment for GLUT1 Deficiency Syndrome

Juan M. PascualPI

Intervention: Other: Red Blood Cell Transfusion
Dates: Sep 2027 – Aug 2030 (est.)
Sponsor: Weill Medical College of Cornell University

Glucose Transporter Type 1 Deficiency SyndromeGLUT1DS1

‹ Prev 1 2 3 4 5 6 7…56 57 58 59 60 Next ›